Dr. Yue Lu is an Assistant Professor in the Department of Molecular Pharmaceutics at the University of Utah, and a member of the Experimental Therapeutics Program at the Huntsman Cancer Institute. She received her B.S. degree in Chemistry from Nanjing University, and Ph.D. at the University of North Carolina at Chapel Hill and North Carolina (NC) State University, under the guidance of Dr. Zhen Gu in the Joint Department of Biomedical Engineering. She completed her postdoctoral fellowship with Dr. James R. Heath at the Institute for Systems Biology and Caltech. Dr. Lu is the recipient of the Graduate Research Advances in Delivery Science Award from the Controlled Release Society, the Chinese Government Award for Outstanding Self-financed Students Abroad, and the Distinguished Graduate Dissertation Award from NC State College of Engineering.
RESEARCH INTERESTS
The Lu Digital Pharmaceutics (DigiPharma) Laboratory aims to develop and apply state-of-the-art technologies to understand disease pathologies and develop treatment strategies for cancer, infectious diseases, and autoimmune diseases. In particular, we are pursuing the following three directions:
Spatial Tissue Profiling: We integrate spatial omics with pharmaceutics to determine the factors that influence treatment response and develop data-driven precision cancer immunotherapies.
Single Extracellular Vesicle Analysis: We harness the rich information carried by extracellular vesicles to monitor blood-borne tissue and disease-specific signatures and develop biomimetic drug delivery technologies.
Health Monitoring Devices: We develop microfluidic devices to monitor the health and therapeutic response of patients and learn how to transition back to a healthy state.
RELATED LINKS
Education History
| Undergraduate |
Nanjing University |
BS, Chemistry |
|---|---|---|
| Doctoral Training |
University of North Carolina at Chapel Hill |
PhD, Biomedical Engineering |
|
California Institute of Technology, Institute for Systems Biology |
Postdoctoral Fellow |
Selected Publications
Journal Article
-
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial.
Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, Ji Y, Dvorkin M, Shi J, Pan Z, Shi J, Wang X, Bai Y, Melkadze T, Pan Y, Min X, Viguro M, Li X, Zhao Y, Yang J, Makharadze T, Arkania E, Kang W, Wang Q, Zhu J; ASTRUM-005 Study Group. JAMA. 2022 Sep 27;328(12):1223-1232. doi: 10.1001/jama.2022.16464. PMID: 36166026 Free PMC article. Clinical Trial. -
Non-viral precision T cell receptor replacement for personalized cell therapy. Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, Ma Y, Lu W, Peng S, Wang CL, Yuen B, Dalmas O, Heeringa K, Sennino B, Conroy A, Bethune MT, Mende I, White W, Kukreja M, Gunturu S, Humphrey E, Hussaini A, An D, Litterman AJ, Quach BB, Ng AHC, Lu Y, Smith C, Campbell KM, Anaya D, Skrdlant L, Huang EY, Mendoza V, Mathur J, Dengler L, Purandare B, Moot R, Yi MC, Funke R, Sibley A, Stallings-Schmitt T, Oh DY, Chmielowski B, Abedi M, Yuan Y, Sosman JA, Lee SM, Schoenfeld AJ, Baltimore D, Heath JR, Franzusoff A, Ribas A, Rao AV, Mandl SJ. Nature. 2023 Mar;615(7953):687-696. doi: 10.1038/s41586-022-05531-1. Epub 2022 Nov 10. PMID: 36356599 Free PMC article. Clinical Trial.
-
Safranal Alleviated OVA-Induced Asthma Model and Inhibits Mast Cell Activation.
Lertnimitphun P, Zhang W, Fu W, Yang B, Zheng C, Yuan M, Zhou H, Zhang X, Pei W, Lu Y, Xu H. Front Immunol. 2021 May 20;12:585595. doi: 10.3389/fimmu.2021.585595. eCollection 2021. PMID: 34093515 Free PMC article.